Cargando…
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
It is now well accepted that the immune system can control cancer growth. However, tumors escape immune-mediated control through multiple mechanisms and the downregulation or loss of major histocompatibility class (MHC)-I molecules is a common immune escape mechanism in many cancers. MHC-I molecules...
Autores principales: | Shklovskaya, Elena, Rizos, Helen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268865/ https://www.ncbi.nlm.nih.gov/pubmed/34201655 http://dx.doi.org/10.3390/ijms22136741 |
Ejemplares similares
-
Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy
por: Shklovskaya, Elena, et al.
Publicado: (2020) -
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
por: Lee, Jenny H., et al.
Publicado: (2020) -
Selective acceptance of MHC class I-deficient tumor grafts in the brain
Publicado: (1988) -
MHC class I multimers
por: Sun, Mei-Yi, et al.
Publicado: (2001) -
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
por: Shklovskaya, Elena, et al.
Publicado: (2020)